Doxorubicin is one of the most commonly prescribed and time-tested anticancer drugs. Although being considered as a first line drug in different types of cancers, the two main obstacles to doxorubicin therapy are drug-induced cardiotoxicity and drug resistance.
Method
The study utilizes systemic reviews on publications of previous studies obtained from scholarly journal databases including PubMed, Medline, Ebsco Host, Google Scholar, and Cochrane. The study utilizes secondary information obtained from health organizations using filters and keywords to sustain information relevancy. The study utilizes information retrieved from studies captured in the peer-reviewed journals on “doxorubicin-induced cardiotoxicity” and “doxorubicin resistance.”
Discussion and results
The exact mechanisms of cardiotoxicity are not known; various hypotheses are studied. Doxorubicin can lead to free radical generation in various ways. The commonly proposed underlying mechanisms promoting doxorubicin resistance are the expression of multidrug resistance proteins as well as other causes.
Conclusion
In this review, we have described the major obstacles to doxorubicin therapy, doxorubicin-induced cardiotoxicity as well as the mechanisms of cancer drug resistance and in following the treatment failures.
MohajeriMSahebkarA. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review. Crit Rev Oncol Hematol2018; 122: 30–51.
2.
GabizonAShmeedaHBarenholzY. Clin Pharmacokinet. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet2003; 42: 419–436.
3.
MorabitoAGattusoDStaniSC, et al.Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat2004; 86: 249–258.
4.
SingalPLiTKumarD, et al.Adriamycin-induced heart failure: mechanisms and modulation. Mol Cell Biochem2000; 207: 77–86.
5.
NovitzkyNThomasVAbrahamsL, et al.Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Am J Hematol2004; 76: 319–329.
6.
ThornCFOshiroCMarshS, et al.Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom2011; 21: 440–446.
7.
KimSYKimSJKimBJ, et al.Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med2006; 38: 535–535.
8.
KimSBKimJSLeeJH, et al.NF-κB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells. FEBS Lett2006; 580: 311–318.
9.
KobayashiSVoldenPTimmD, et al.Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem2010; 285: 793–804.
10.
MoiseenkoFBogdanovADubinaM, et al.Resistance mechanisms to drug therapy in breast cancer and other solid tumors: an opinion. F1000 Res2017; 6: 288–288.
11.
SmithTWolffKANguyenL. Molecular biology of drug resistance in mycobacterium tuberculosis. Curr Top Microbiol Immunol2014; 374: 53–80.
12.
GewirtzDA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol1999; 57: 727–741.
13.
SinhaBKMimnaughEG. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med1990; 8: 567–581.
14.
PawłowskaJTarasiukJWolfCR, et al.Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res2003; 13: 245–252.
15.
FogliSNieriPBreschiMC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J2004; 18: 664–675.
16.
FrankNECusackBJTalleyTT, et al.Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model. Invest New Drugs2016; 34: 693–700.
17.
ChenSHChanNLHsiehTS. New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem2013; 82: 139–170.
18.
RoosWPKainaB. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett2013; 332: 237–248.
19.
LotemJPeled-KamarMGronerY, et al.Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines. Proc Natl Acad Sci USA1996; 93: 9166–9171.
20.
AllenA. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol1992; 19: 529–542.
21.
JainD. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol2000; 7: 53–62.
22.
LipshultzSELipsitzSRMoneSM, et al.Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med1995; 332: 1738–1743.
23.
LanzariniLBossiGLaudisaML, et al.Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J2000; 140: 315–323.
24.
SorensenKLevittGSebag-MontefioreD, et al.Cardiac function in Wilms' tumor survivors. J Clin Oncol1995; 13: 1546–1556.
25.
SilberJHJakackiRILarsenRL, et al.Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol1993; 21: 477–479.
26.
TuzovicMWuPTKianmahdS, et al.Natural history of myocardial deformation in children, adolescents, and young adults exposed to anthracyclines: systematic review and meta-analysis. Echocardiography2018; 35: 922–934.
27.
HershmanDLMcBrideRBEisenbergerA, et al.Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol2008; 26: 3159–3165.
28.
GodoyLYFukushigeJIgarashiH, et al.Anthracycline-induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn1997; 39: 188–193.
29.
PeinFSakirogluODahanM, et al.Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer2004; 91: 37–44.
30.
ShabalalaSMullerCJFLouwJ, et al.Polyphenols, autophagy and doxorubicin-induced cardiotoxicity. Life Sci2017; 180: 160–170.
31.
KremerLCVan DalenECOffringaM, et al.Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol2002; 13: 503–512.
32.
XuMFTangPLQianZM, et al.Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci2001; 68: 889–901.
33.
ŠimůnekTŠtěrbaMPopelováO, et al.Anthracycline induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep2009; 61: 154–171.
GoormaghtighEChatelainPCaspersJ, et al.Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. Biochem Pharmacol1980; 29: 3003–3010.
36.
SchlameMRuaDGreenbergML. The biosynthesis and functional role of cardiolipin. Prog Lipid Res2000; 39: 257–288.
37.
YoonHRHongYMBoriackRL, et al.Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats. Pediatr Res2003; 53: 788–792.
38.
CarvalhoRASousaRPCadeteVJ, et al.Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology2010; 270: 92–98.
39.
SulimanHBCarrawayMSAliAS, et al.The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest2007; 117: 3730–3741.
40.
PaniGBedogniBAnzevinoR, et al.Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res2000; 60: 4654–4660.
41.
KimDSKimHRWooER, et al.Protective effect of calceolarioside on adriamycin-induced cardiomyocyte toxicity. Eur J Pharmacol2006; 541: 24–32.
42.
Vásquez-VivarJMartasekPHoggN, et al.Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry1997; 36: 11293–11297.
43.
KalivendiSVKotamrajuSZhaoH, et al.Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J BiolChem2001; 276: 47266–47276.
44.
NeilanTGBlakeSLIchinoseF, et al.Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation2007; 116: 506–514.
45.
DuquaineDHirschGAChakrabartiA, et al.Rapidonset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med2003; 8: 101–107.
46.
MukhopadhyayPRajeshMBátkaiS, et al.Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol2009; 296: H1466–H1483.
47.
FuJYamamotoKGuanZW, et al.Human neuronal nitric oxide synthase can catalyze one-electron reduction of adriamycin: role of flavin domain. Arch Biochem Biophys2004; 427: 180–187.
48.
LiuBLiHQuH, et al.Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. J Biochem Mol Biol2006; 39: 759–765.
49.
DengSKrugerAKleschyovAL, et al.Gp91phoxcontaining NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med2007; 42: 466–473.
50.
GilleronMMarechalXMontaigneD, et al.NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun2009; 388: 727–731.
51.
GuenanciaCLiNHachetO, et al.Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice. Toxicol Appl Pharmacol2015; 284: 152–162.
52.
XuXPerssonHLRichardsonDR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol2005; 68: 261–271.
53.
MinottiGRecalcatiSMordenteA, et al.The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J1998; 12: 541–552.
54.
PanjrathGSPatelVValdiviezoCI, et al.Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol2007; 49: 2457–2464.
55.
LudwigHEvstatievRKornekG, et al.Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr2015; 127: 907–919.
56.
DhallaNSTemsahRMNetticadanT. Role of oxidative stress in cardiovascular diseases. J Hypertens2000; 18: 655–673.
57.
BjelogrlicSKRadicJJovicV, et al.Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice. Basic Clin Pharmacol Toxicol2005; 97: 311–319.
58.
LiuBBaiQXChenXQ, et al.Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi2007; 15: 762–766.
59.
VedamKNishijimaYDruhanLJ, et al.Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. Am J Physiol Heart Circ Physiol2010; 298: H1832–H1841.
60.
NozakiNShishidoTTakeishiY, et al.Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation2004; 110: 2869–2874.
61.
RiadABienSGratzM, et al.Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail2008; 10: 233–243.
62.
ChenCJinY. Effects of oxymatrine on expression of nuclear factor kappa B in kidneys of rats with adriamycin-induced chronic renal fibrosis. Nan Fang Yi Ke Da Xue Xue Bao2007; 27: 345–348.
63.
UenoMKakinumaYYuhkiKI, et al.Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci2006; 101: 151–158.
64.
YounHJKimHSJeonMH, et al.Induction of caspase independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol Cell Biochem2005; 270: 13–19.
65.
MaejimaYAdachiSMorikawaK, et al.Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol2005; 38: 163–174.
66.
KalivendiSVKonorevEACunninghamS, et al.Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J2005; 389: 527–539.
67.
AraiMYoguchiATakizawaT, et al.Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res2000; 86: 8–14.
68.
SaekiKObiIOgikuN, et al.Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci2002; 70: 2377–2389.
69.
OlsonRDGamblielHAVestalRE, et al.Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol2005; 5: 269–283.
70.
FaveroTGZableACAbramsonJJ. Hydrogen peroxide stimulates the Ca2+ release channel from skeletal muscle sarcoplasmic reticulum. J Biol Chem1995; 270: 25557–25563.
71.
JangYMKendaiahSDrewB, et al.Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett2004; 577: 483–490.
72.
LimCCZuppingerCGuoX, et al.Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem2004; 279: 8290–8299.
73.
SolemLEHellerLJWallaceKB. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J Mol Cell Cardiol1996; 28: 1023–1032.
74.
ChaconEUlrichRAcostaD. A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes. Biochem1992; 281: 871–878.
75.
GabrielsonKBedjaDPinS, et al.Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res2007; 67: 1436–1441.
76.
SuzukiTMiyauchiT. A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes. Am J Physiol Regul Integr Comp Physiol2001; 280: R1399–R1406.
77.
Sayed-AhmedMMKhattabMMGadMZ, et al.Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol2001; 89: 140–144.
78.
LüscherTFBartonM. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation2000; 102: 2434–2440.
79.
BienSRiadARitterCA, et al.The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res2007; 67: 10428–10435.
80.
SpallarossaPAltieriPGaribaldiS, et al.Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res2006; 69: 736–745.
81.
SinghBKPathanRAPillaiKK, et al.Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. J Cardiovasc Pharmacol2010; 55: 139–144.
82.
DowdNPScullyMAdderleySR, et al.Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest2001; 108: 585–590.
83.
HorieTOnoKNishiH, et al.Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin–ErbB pathway. Cardiovasc Res2010; 87: 656–664.
84.
Andrieu-AbadieNJaffrézouJ-PHatemS, et al.L-Carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J1999; 13: 1501–1510.
85.
MukhopadhyayPBátkaiSRajeshM, et al.Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol2007; 50: 528–536.
86.
Von HoffDDLayardMWBasaP, et al.Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med1979; 91: 710–717.
87.
AliMKEwerMSGibbsHR, et al.Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer1994; 74: 182–188.
88.
ZambettiMMoliterniAMaterazzoC, et al.Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol2001; 19: 37–43.
89.
SchloemerNJ1BricklerMHoffmannR, et al.Administration of dexrazoxane improves cardiac indices in children and young adults with acute myeloid leukemia (AML) while maintaining survival outcomes. J Pediatr Hematol Oncol2017; 39: e254–e258.
90.
TahoverElSegalAIsacsonR, et al.Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival. Anticancer Drugs2017; 28: 787–794.
91.
YamanakaSTatsumiTShiraishiJ, et al.Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Cell Cardiol2003; 41: 870–878.
92.
Al-MalkyHSOsmanAMDamanhouriZA, et al.Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals. Cancer Cell Int2019; 19: 191–191.
93.
HsuWTHuangCYYenCYT, et al.The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling. Theranostics2018; 8: 3176–3188.
94.
BorstPEversRKoolM, et al.A family of drug transporters: the multidrug resistance-associated proteins. J Nat Canc Inst2000; 92: 1295–1302.
95.
SchinkelAHKempSDolleM, et al.N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem1993; 268: 7474–7481.
96.
RoyUBarberPBatrakovaEV, et al.Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections. Front Microbiol2015; 6: 948–948.
97.
ZahreddineHBordenKL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol2013; 4: 1–8.
98.
MansooriBMohammadiADavudianS, et al.The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull2017; 7: 339–348.
99.
KoleiniNKardamiE. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget2017; 8: 46663–46680.
100.
CoxJWeinmanS. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepatic Oncol2016; 3: 57–59.
101.
SrivalliKLakshmiPK. Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharm Sci2012; 48: 353–367.
102.
NitissJL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer2009; 9: 338–350.
103.
PressMFSauterGBuyseM, et al.Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol2011; 29: 859–867.
104.
PanvichianRTantiwetrueangdetAAngkathunyakulN, et al.TOP2A amplification and overexpression in hepatocellular carcinoma tissues. Biomed Res Int2015; 381602: 1–8.
105.
WongNYeoWWongWL, et al.TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer2009; 124: 644–652.
106.
OkadaYTosakaANimuraY, et al.Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene2001; 272: 141–148.
107.
RyanKMPhillipsACVousdenKH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol2001; 13: 332–337.
108.
HientzKMohrABhakta-GuhaD, et al.The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget2017; 8: 8921–8921.
109.
WangZSunY. Targeting p53 for novel anticancer therapy. Trans Oncol2010; 3: 1–12.
110.
MarinJJGRomeroMRMartinez-BecerraP, et al.Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med2009; 9: 1108–1129.
111.
FarhanMWangHGaurU, et al.FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci2017; 13: 815–815.
112.
HuiRCFrancisREGuestSK, et al.Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther2008; 7: 670–678.
113.
GomesARZhaoFLamEW. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. Chin J Cancer2013; 32: 365–365.
114.
ZhangXTangNHaddenTJ, et al.Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta2011; 1813: 1978–1986.
115.
ManovIPollakYBroneshterR, et al.Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib – the role of extracellular signal-regulated kinase counteraction. FEBS J2011; 278: 3494–507.
116.
TormoEPinedaBSernaE, et al.MicroRNA profile in response to doxorubicin treatment in breast cancer. J Cell Biochem2015; 116: 2061–2073.
